Stock Analysis on Net
Stock Analysis on Net

Gilead Sciences Inc. (NASDAQ:GILD)

Common-Size Income Statement
Quarterly Data

Gilead Sciences Inc., common-size consolidated income statement (quarterly data)

Microsoft Excel
3 months ended: Dec 31, 2023 Sep 30, 2023 Jun 30, 2023 Mar 31, 2023 Dec 31, 2022 Sep 30, 2022 Jun 30, 2022 Mar 31, 2022 Dec 31, 2021 Sep 30, 2021 Jun 30, 2021 Mar 31, 2021 Dec 31, 2020 Sep 30, 2020 Jun 30, 2020 Mar 31, 2020 Dec 31, 2019 Sep 30, 2019 Jun 30, 2019 Mar 31, 2019
Product sales 100.00 100.00 100.00 100.00 100.00 100.00 100.00 100.00 100.00 100.00 100.00 100.00 100.00 100.00 100.00 100.00 100.00 100.00 100.00 100.00
Cost of goods sold -29.56 -22.38 -21.97 -22.22 -19.04 -19.99 -23.49 -21.79 -36.69 -16.63 -22.59 -21.47 -19.08 -17.57 -21.00 -17.72 -29.04 -18.76 -17.83 -18.40
Gross profit on product sales 70.44% 77.62% 78.03% 77.78% 80.96% 80.01% 76.51% 78.21% 63.31% 83.37% 77.41% 78.53% 80.92% 82.43% 79.00% 82.28% 70.96% 81.24% 82.17% 81.60%
Royalty, contract and other revenues 0.62 0.81 0.53 0.73 0.78 0.92 1.99 0.86 1.17 0.88 1.06 1.31 1.27 1.29 1.50 1.48 1.43 1.60 1.39 1.56
Research and development expenses -19.90 -20.83 -21.44 -22.95 -21.11 -16.47 -17.95 -18.03 -28.31 -15.59 -18.43 -16.64 -21.53 -17.83 -25.64 -18.36 -18.96 -18.67 -17.75 -17.90
Acquired in-process research and development expenses -4.91 -1.30 -3.60 -7.63 -2.15 -6.42 -5.38 -0.12 0.00 -0.26 -1.56 -0.98 -0.87 -18.03 -89.28 -1.77 -13.80 -71.79 -2.94 -2.42
In-process research and development impairment -0.71 0.00 0.00 0.00 0.00 0.00 0.00 -41.32 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Selling, general and administrative expenses -22.74 -18.80 -28.17 -20.90 -27.55 -17.38 -22.11 -16.57 -23.04 -16.18 -21.96 -16.64 -23.61 -17.03 -24.45 -19.68 -20.77 -19.07 -19.53 -19.81
Operating income (loss) 22.80% 37.50% 25.37% 27.04% 30.92% 40.66% 33.06% 3.01% 13.13% 52.23% 36.51% 45.58% 36.18% 30.82% -58.87% 43.94% 18.86% -26.70% 43.34% 43.02%
Interest expense -3.56 -3.32 -3.50 -3.65 -3.08 -3.28 -3.94 -3.64 -3.32 -3.40 -4.16 -4.05 -3.64 -3.63 -4.74 -4.41 -4.19 -4.53 -4.42 -4.88
Other income (expense), net 4.14 -1.04 2.33 -2.78 -0.14 -2.52 -4.63 -1.70 0.80 -2.09 -2.81 -5.82 -7.78 -14.48 4.93 -2.89 18.13 4.02 4.07 7.06
Income (loss) before income taxes 23.38% 33.14% 24.19% 20.62% 27.70% 34.85% 24.49% -2.33% 10.60% 46.74% 29.54% 35.71% 24.75% 12.71% -58.67% 36.64% 32.80% -27.21% 42.98% 45.19%
Income tax (expense) benefit -3.34 -2.09 -8.36 -5.00 -5.43 -9.26 -6.00 2.51 -5.35 -11.58 -4.88 -8.55 -3.68 -7.27 -7.36 -8.51 13.60 6.04 -9.54 -7.35
Net income (loss) 20.04% 31.06% 15.83% 15.62% 22.27% 25.59% 18.49% 0.18% 5.25% 35.15% 24.66% 27.16% 21.07% 5.44% -66.04% 28.13% 46.39% -21.17% 33.44% 37.85%
Net loss attributable to noncontrolling interest 0.18 0.11 0.09 0.40 0.10 0.04 0.15 0.11 0.08 0.08 0.08 0.11 0.10 0.11 0.14 0.24 0.12 0.05 0.09 0.13
Net income (loss) attributable to Gilead 20.23% 31.17% 15.92% 16.02% 22.37% 25.64% 18.64% 0.29% 5.34% 35.24% 24.74% 27.27% 21.17% 5.54% -65.90% 28.37% 46.51% -21.12% 33.53% 37.98%

Based on: 10-K (reporting date: 2023-12-31), 10-Q (reporting date: 2023-09-30), 10-Q (reporting date: 2023-06-30), 10-Q (reporting date: 2023-03-31), 10-K (reporting date: 2022-12-31), 10-Q (reporting date: 2022-09-30), 10-Q (reporting date: 2022-06-30), 10-Q (reporting date: 2022-03-31), 10-K (reporting date: 2021-12-31), 10-Q (reporting date: 2021-09-30), 10-Q (reporting date: 2021-06-30), 10-Q (reporting date: 2021-03-31), 10-K (reporting date: 2020-12-31), 10-Q (reporting date: 2020-09-30), 10-Q (reporting date: 2020-06-30), 10-Q (reporting date: 2020-03-31), 10-K (reporting date: 2019-12-31), 10-Q (reporting date: 2019-09-30), 10-Q (reporting date: 2019-06-30), 10-Q (reporting date: 2019-03-31).

Income statement item Description The company
Operating income (loss) The net result for the period of deducting operating expenses from operating revenues. Gilead Sciences Inc. operating income (loss) as a percentage of product sales increased from Q2 2023 to Q3 2023 but then decreased significantly from Q3 2023 to Q4 2023.
Income (loss) before income taxes Amount of income (loss) from continuing operations, including income (loss) from equity method investments, before deduction of income tax expense (benefit), and income (loss) attributable to noncontrolling interest. Gilead Sciences Inc. income (loss) before income taxes as a percentage of product sales increased from Q2 2023 to Q3 2023 but then decreased significantly from Q3 2023 to Q4 2023.
Net income (loss) attributable to Gilead The portion of profit or loss for the period, net of income taxes, which is attributable to the parent. Gilead Sciences Inc. net income (loss) attributable to Gilead as a percentage of product sales increased from Q2 2023 to Q3 2023 but then slightly decreased from Q3 2023 to Q4 2023 not reaching Q2 2023 level.